- Home
- EXP vs ROIV Comparison
EXP vs ROIV Comparison
Compare EXP & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXP | ROIV |
|---|---|---|
| Founded | 1963 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 14.1B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXP | ROIV |
|---|---|---|
| Price | $221.03 | $21.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $236.25 | $24.31 |
| AVG Volume (30 Days) | 446.4K | ★ 8.4M |
| Earning Date | 01-28-2026 | 02-09-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 13.52 | N/A |
| Revenue | ★ $2,301,796,000.00 | $20,329,000.00 |
| Revenue This Year | $2.76 | N/A |
| Revenue Next Year | $3.57 | $741.42 |
| P/E Ratio | $15.42 | ★ N/A |
| Revenue Growth | ★ 1.50 | N/A |
| 52 Week Low | $191.91 | $8.73 |
| 52 Week High | $265.42 | $23.47 |
Technical Indicators
Market Signals| Indicator | EXP | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 54.75 | 51.67 |
| Support Level | $207.29 | $21.15 |
| Resistance Level | $218.72 | $22.14 |
| Average True Range (ATR) | 6.01 | 0.65 |
| MACD | 0.06 | -0.14 |
| Stochastic Oscillator | 70.84 | 43.91 |
Price Performance
Historical ComparisonAbout EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.